- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
-
Lee DY
- KMID: 2548164
- Diabetes Metab J.
- 2023 Nov;47(6):879-881.
- doi: 10.4093/dmj.2023.0328
-
- CITED
-
- Close
- SHARE
-
- Close
- Navigating the Future of Diabetes Treatment with New Drugs: Focusing on the Possibilities and Prospects of Enavogliflozin
-
Rhee SY
- KMID: 2548153
- Diabetes Metab J.
- 2023 Nov;47(6):769-770.
- doi: 10.4093/dmj.2023.0351
-
- CITED
-
- Close
- SHARE
-
- Close
- Ensuring Heathy Lives with the Korea Disease Control and Prevention Agency: Partnership with the Korean Diabetes Association
-
Jee Y
- KMID: 2548152
- Diabetes Metab J.
- 2023 Nov;47(6):767-768.
- doi: 10.4093/dmj.2023.0406
-
- CITED
-
- Close
- SHARE
-
- Close
- Glimepiride Compared to Liraglutide Increases Plasma Levels of miR-206, miR-182-5p, and miR-766-3p in Type 2 Diabetes Mellitus: A Randomized Controlled Trial (Diabetes Metab J 2023;47:668-81)
-
Scherbak NN, Kruse R, Nyström T, Jendle J
- KMID: 2548165
- Diabetes Metab J.
- 2023 Nov;47(6):882-883.
- doi: 10.4093/dmj.2023.0355
-
- CITED
-
- Close
- SHARE
-
- Close
- Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice
-
Cho YK, Jung CH
- KMID: 2548151
- Diabetes Metab J.
- 2023 Nov;47(6):757-766.
- doi: 10.4093/dmj.2023.0072
With the increasing use of immune-checkpoint inhibitors (ICIs), such as anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and anti-programmed cell death-1 (PD-1), for the treatment of malignancies, cases of ICI-induced type... -
- CITED
-
- Close
- SHARE
-
- Close
- Comparison of on-Statin Lipid and Lipoprotein Levels for the Prediction of First Cardiovascular Event in Type 2 Diabetes Mellitus
-
Kim JY, Choi J, Kim SG, Kim NH
- KMID: 2548160
- Diabetes Metab J.
- 2023 Nov;47(6):837-845.
- doi: 10.4093/dmj.2022.0217
Background: A substantial cardiovascular disease risk remains even after optimal statin therapy. Comparative predictiveness of major lipid and lipoprotein parameters for cardiovascular events in patients with type 2 diabetes mellitus... -
- CITED
-
- Close
- SHARE
-
- Close
- Pharmacological and Nonpharmacological Treatments for Painful Diabetic Peripheral Neuropathy
-
Jang HN, Oh TJ
- KMID: 2548150
- Diabetes Metab J.
- 2023 Nov;47(6):743-756.
- doi: 10.4093/dmj.2023.0018
Diabetic peripheral neuropathy (DPN) is one of the most prevalent chronic complications of diabetes. The lifetime prevalence of DPN is thought to be >50%, and 15%–25% of patients with diabetes... -
- CITED
-
- Close
- SHARE
-
- Close
- The Risk of Shoulder Adhesive Capsulitis in Individuals with Prediabetes and Type 2 Diabetes Mellitus: A Longitudinal Nationwide Population-Based Study
-
Kim JH, Kim BS, Han Kd, Kwon HS
- KMID: 2548163
- Diabetes Metab J.
- 2023 Nov;47(6):869-878.
- doi: 10.4093/dmj.2022.0275
Background: This study aimed to investigate the association between type 2 diabetes mellitus (T2DM) and shoulder adhesive capsulitis (AC) using a large-scale, nationwide, population-based cohort in the Republic of Korea. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Enavogliflozin versus Dapagliflozin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus: A 24-Week, Double-Blind, Randomized Trial
-
Han KA, Kim YH, Kim DM, Lee BW, Chon S, Sohn TS, Jeong IK, Hong EG, Son JW, Nah JJ, Song HR, Cho SI, Cho SA, Yoon KH
- KMID: 2548156
- Diabetes Metab J.
- 2023 Nov;47(6):796-807.
- doi: 10.4093/dmj.2022.0315
Background: Enavogliflozin is a novel sodium-glucose cotransporter-2 inhibitor currently under clinical development. This study evaluated the efficacy and safety of enavogliflozin as an add-on to metformin in Korean patients with... -
- CITED
-
- Close
- SHARE
-
- Close
- Differential Impact of Obesity on the Risk of Diabetes Development in Two Age Groups: Analysis from the National Health Screening Program
-
Yoo TK, Han KD, Kim YH, Nam GE, Park SH, Rhee EJ, Lee WY
- KMID: 2548161
- Diabetes Metab J.
- 2023 Nov;47(6):846-858.
- doi: 10.4093/dmj.2022.0242
Background: The effect of obesity on the development of type 2 diabetes mellitus (DM) in different age groups remains unclear. We assessed the impact of obesity on the development of... -
- CITED
-
- Close
- SHARE
-
- Close
- Type 2 Diabetes Mellitus and Sarcopenia as Comorbid Chronic Diseases in Older Adults: Established and Emerging Treatments and Therapies
-
Mesinovic J, Fyfe JJ, Talevski J, Wheeler MJ, Leung GK, George ES, Hunegnaw MT, Glavas C, Jansons P, Daly RM, Scott D
- KMID: 2548149
- Diabetes Metab J.
- 2023 Nov;47(6):719-742.
- doi: 10.4093/dmj.2023.0112
Type 2 diabetes mellitus (T2DM) and sarcopenia (low skeletal muscle mass and function) share a bidirectional relationship. The prevalence of these diseases increases with age and they share common risk... -
- CITED
-
- Close
- SHARE
-
- Close
- Effects Of Exercise Training And Chlorogenic Acid Supplementation On Hepatic Lipid Metabolism In Prediabetes Mice
-
Shirkhani S, Marandi SM, Nasr-Esfahani MH, Kim SK
- KMID: 2548154
- Diabetes Metab J.
- 2023 Nov;47(6):771-783.
- doi: 10.4093/dmj.2022.0265
Background: Since prediabetes is a risk factor for metabolic syndromes, it is important to promote a healthy lifestyle to prevent prediabetes. This study aimed to determine the effects of green... -
- CITED
-
- Close
- SHARE
-
- Close
- Altered Metabolic Phenotypes and Hypothalamic Neuronal Activity Triggered by Sodium-Glucose Cotransporter 2 Inhibition
-
Lee HG, Jung IH, Park BS, Yang HR, Kim KK, Tu TH, Yeh JY, Lee S, Yang S, Lee BJ, Kim JG, Nam-Goong IS
- KMID: 2548155
- Diabetes Metab J.
- 2023 Nov;47(6):784-795.
- doi: 10.4093/dmj.2022.0261
Background: Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are currently used to treat patients with diabetes. Previous studies have demonstrated that treatment with SGLT-2 inhibitors is accompanied by altered metabolic phenotypes. However,... -
- CITED
-
- Close
- SHARE
-
- Close
- Clinical and Lifestyle Determinants of Continuous Glucose Monitoring Metrics in Insulin-Treated Patients with Type 2 Diabetes Mellitus
-
Lee DY, Kim N, Jung I, Park SY, Yu JH, Seo JA, Kim J, Kim KJ, Kim NH, Yoo HJ, Kim SG, Choi KM, Baik SH, Park SM, Kim NH
- KMID: 2548159
- Diabetes Metab J.
- 2023 Nov;47(6):826-836.
- doi: 10.4093/dmj.2022.0273
Background: There was limited evidence to evaluate the association between lifestyle habits and continuous glucose monitoring (CGM) metrics. Thus, we aimed to depict the behavioral and metabolic determinants of CGM... -
- CITED
-
- Close
- SHARE
-
- Close
- The Efficacy and Safety of Moderate-Intensity Rosuvastatin with Ezetimibe versus High-Intensity Rosuvastatin in High Atherosclerotic Cardiovascular Disease Risk Patients with Type 2 Diabetes Mellitus: A Randomized, Multicenter, Open, Parallel, Phase 4 Study
-
Moon JS, Park IR, Kim SS, Kim HS, Kim NH, Kim SG, Ko SH, Lee JH, Lee I, Lee BK, Won KC
- KMID: 2548158
- Diabetes Metab J.
- 2023 Nov;47(6):818-825.
- doi: 10.4093/dmj.2023.0171
Background: To investigate the efficacy and safety of moderate-intensity rosuvastatin/ezetimibe combination compared to highintensity rosuvastatin in high atherosclerotic cardiovascular disease (ASCVD) risk patients with type 2 diabetes mellitus (T2DM). Methods: This... -
- CITED
-
- Close
- SHARE
-
- Close
- Prediabetes Progression and Regression on Objectively- Measured Physical Function: A Prospective Cohort Study
-
Qiu S, Zhu Y, Xie B, Chen W, Wang D, Cai X, Sun Z, Wu T
- KMID: 2548162
- Diabetes Metab J.
- 2023 Nov;47(6):859-868.
- doi: 10.4093/dmj.2022.0377
Background: Prediabetes leads to declines in physical function in older adults, but the impact of prediabetes progression or regression on physical function is unknown. This study assessed this longitudinal association,... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
-
Moon JS, Park IR, Kim HJ, Chung CH, Won KC, Han KA, Park CY, Won JC, Kim DJ, Koh GP, Kim ES, Yu JM, Hong EG, Lee CB, Yoon KH
- KMID: 2548157
- Diabetes Metab J.
- 2023 Nov;47(6):808-817.
- doi: 10.4093/dmj.2022.0387
Background: This study investigates the long-term efficacy and safety of evogliptin add-on therapy in patients with inadequately controlled type 2 diabetes mellitus (T2DM) previously received dapagliflozin and metformin (DAPA/MET) combination. Methods:... -
- CITED
-
- Close
- SHARE
-
- Close
